fam50a Antibody

What is FAM50A and what cellular functions does this protein perform?

FAM50A (Family with Sequence Similarity 50 Member A) is a highly conserved nuclear protein belonging to the FAM50 family. It contains a nuclear localization signal and functions as a DNA-binding protein or transcription factor . Recent research has revealed that FAM50A plays a critical role in pre-mRNA splicing regulation, particularly in skipped exon (SE) events which account for approximately 67% of alternative splicing events it regulates . The protein is approximately 40 kDa (observed molecular weight) with a calculated size of 39 kDa (325 amino acids) . FAM50A is highly conserved across different species, suggesting evolutionary importance in fundamental cellular processes. It has been implicated in intellectual disability syndromes when mutated, and recent evidence indicates its involvement in cancer progression through splicing regulation mechanisms .

Which FAM50A antibody applications are most reliable for detecting endogenous protein?

Based on validation data across multiple studies, Western blot (WB) and immunohistochemistry (IHC) represent the most reliable applications for detecting endogenous FAM50A protein. The Proteintech antibody (19849-1-AP) has been validated extensively for these applications with the following specifications:

For immunocytochemistry/immunofluorescence (ICC/IF), the Abcam monoclonal antibody [EPR12816] (ab186410) has demonstrated specific nuclear staining, reflecting FAM50A's predominant subcellular localization . When designing experiments, it is advisable to optimize antibody concentrations for each specific cell line or tissue type, as expression levels may vary significantly across different biological samples .

How should researchers prepare samples for optimal FAM50A detection in immunohistochemistry?

For optimal FAM50A detection in IHC applications, tissue processing and antigen retrieval are critical steps. The recommended protocol includes:

• Fixation in 10% neutral buffered formalin followed by paraffin embedding

• Sectioning at 4-6 μm thickness

• Primary antigen retrieval with TE buffer (pH 9.0) for optimal results

• Alternative antigen retrieval with citrate buffer (pH 6.0) may be performed if needed

• Blocking with normal serum from the same species as the secondary antibody

• Primary antibody incubation at 1:1000-1:4000 dilution (optimal dilution should be determined empirically)

• Detection with appropriate secondary antibody system

The antibody has been successfully validated on rat colon and kidney tissues, showing specific nuclear staining patterns . For human tissue samples, additional optimization may be required to account for potential differences in protein expression or epitope accessibility.

How can FAM50A antibodies be utilized to investigate its role in pre-mRNA splicing?

FAM50A has been identified as an essential splicing factor that regulates alternative splicing events. Researchers can employ the following methodologies using FAM50A antibodies to study this function:

• RNA Immunoprecipitation (RIP): Using validated FAM50A antibodies to pull down FAM50A-RNA complexes, followed by sequencing to identify bound RNA targets.

• Co-Immunoprecipitation (Co-IP): FAM50A antibodies can be used to identify protein-protein interactions with other splicing factors. This approach has revealed FAM50A's association with spliceosomal components.

• Chromatin Immunoprecipitation (ChIP): To investigate potential interactions between FAM50A and chromatin, especially in the context of co-transcriptional splicing regulation.

• Immunofluorescence co-localization: Dual staining with FAM50A antibodies and known splicing factors can reveal spatial relationships within nuclear speckles or other splicing-related structures.

Recent studies have shown that FAM50A knockout leads to distinct alternative splicing profiles, with significant effects on skipped exon (SE) events (67% of affected transcripts) and alternative 3' splice site selection (A3SS, 20% in KSHV-transformed cells) . Specifically, FAM50A regulates SHP2 alternative splicing, affecting the balance between short (SHP2-S) and long (SHP2-L) isoforms, with downstream effects on STAT3 signaling .

What is the relationship between FAM50A mutations and intellectual disability disorders?

FAM50A mutations have been implicated in Armfield X-linked intellectual disability (XLID) syndrome. Researchers investigating this relationship should consider these methodological approaches:

• Mutation analysis: Western blot analysis with FAM50A antibodies can detect potential changes in protein expression levels or molecular weight shifts in patient-derived samples.

• Subcellular localization studies: Immunofluorescence with FAM50A antibodies can determine whether disease-associated mutations affect nuclear localization. Studies have shown that variants such as p.Trp206Gly, p.Glu254Gly, and p.Asp255Gly do not affect nuclear localization despite their pathogenicity .

• Functional assays: FAM50A antibodies can be used in functional studies to assess how mutations impact protein interactions or splicing activity.

The p.Arg273Trp variant is located in a helix in the high-confidence structure of FAM50A and forms hydrogen bonds with Glu200 and the backbone of Ile199. This mutation potentially affects protein stability . Similarly, the p.Asp255Asn variant introduces a polar residue that disrupts the hydrogen bond with Arg180, potentially affecting FAM50A function despite not altering its subcellular localization .

How can researchers use FAM50A antibodies to investigate its role in cancer biology?

FAM50A has been implicated in tumor progression, particularly in Kaposi's sarcoma-associated herpesvirus (KSHV) induced cellular transformation. Researchers can employ FAM50A antibodies in these cancer-focused applications:

• Expression profiling: Western blot analysis has revealed that FAM50A is significantly upregulated in KSHV-infected cells (KMM) compared to uninfected cells (MM), and in KSHV-infected PEL cell lines (BC3 and BCP1) .

• Tumor tissue analysis: Immunohistochemical staining with FAM50A antibodies on tumor xenografts has confirmed strong FAM50A expression in tumors derived from KSHV-infected cells .

• Mechanistic studies: FAM50A knockout significantly reduces proliferation of KSHV-infected cells, triggers early apoptosis, and induces G0/G1 cell cycle arrest. These phenotypes can be monitored following manipulation of FAM50A expression .

• Downstream pathway analysis: FAM50A regulates SHP2 alternative splicing, which affects STAT3-Y705 phosphorylation. Western blotting with phospho-specific antibodies alongside FAM50A detection can provide insights into this signaling axis .

The table below summarizes key findings regarding FAM50A's role in KSHV-induced oncogenesis:

What factors can affect FAM50A antibody performance in different experimental contexts?

Several factors can influence FAM50A antibody performance across different experimental systems:

• Antibody type selection: Polyclonal antibodies like Proteintech's 19849-1-AP recognize multiple epitopes and may provide higher sensitivity but potentially lower specificity. In contrast, monoclonal antibodies like Abcam's EPR12816 (ab186410) offer higher specificity for a single epitope .

• Protein modifications: Post-translational modifications or protein-protein interactions may mask antibody epitopes in certain cellular contexts. This is particularly relevant for nuclear proteins like FAM50A that participate in large macromolecular complexes.

• Fixation conditions: For immunohistochemistry, antigen retrieval methods significantly impact epitope accessibility. While TE buffer (pH 9.0) is recommended for FAM50A detection, citrate buffer (pH 6.0) provides an alternative when standard protocols yield suboptimal results .

• Expression levels: FAM50A expression varies across cell types and can be altered in disease states. Western blot analysis has shown consistent detection in multiple cell lines (HEK-293, HeLa, Jurkat, NIH/3T3), but optimization may be required for cells with lower expression levels .

• Cross-reactivity: FAM50A antibodies have been tested for reactivity with human, mouse, and rat samples, but potential cross-reactivity with other family members or proteins should be evaluated when working with less characterized systems .

What are the recommended dilutions and validation protocols for FAM50A antibodies?

To ensure reliable results with FAM50A antibodies, follow these application-specific recommendations:

For proper validation, researchers should:

• Include positive controls with known FAM50A expression

• Use negative controls (no primary antibody)

• When possible, include genetic controls (knockout/knockdown)

• Verify subcellular localization (nuclear for FAM50A)

• Confirm expected molecular weight (approximately 40 kDa)

It is important to note that optimal dilutions may vary depending on the specific experimental system, and titration experiments are recommended to determine the ideal concentration for each application and sample type .

How should researchers troubleshoot unexpected results when working with FAM50A antibodies?

When encountering unexpected results with FAM50A antibodies, consider these troubleshooting approaches:

• Multiple band detection in Western blot:

  • Verify sample preparation (complete protein denaturation)

  • Check for protein degradation (add protease inhibitors)

  • Consider post-translational modifications or alternative splicing (FAM50A is involved in splicing regulation)

  • Test different antibody concentrations

• Weak or no signal in IHC/IF:

  • Optimize antigen retrieval (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Increase antibody concentration or incubation time

  • Verify that the sample expresses FAM50A (use positive control tissues)

  • Check fixation conditions (overfixation can mask epitopes)

• High background in IHC/IF:

  • Increase blocking time/concentration

  • Reduce primary antibody concentration

  • Optimize washing steps (increase number or duration)

  • Use more specific detection systems

• Inconsistent results across experiments:

  • Standardize sample preparation protocols

  • Use the same lot of antibody when possible

  • Include internal controls in each experiment

  • Consider variability in FAM50A expression under different cellular conditions

How can FAM50A antibodies be used to investigate its role in disease mechanisms beyond current applications?

FAM50A's emerging roles in intellectual disability disorders and cancer biology suggest several innovative research directions where FAM50A antibodies could provide valuable insights:

• Neurodevelopmental disorders: Given FAM50A mutations' association with X-linked intellectual disability, antibodies could be used to examine protein expression patterns across brain regions during development or in patient-derived cells .

• Cancer progression markers: The significant upregulation of FAM50A in KSHV-induced tumors suggests potential applications in cancer diagnostics or prognostics. Antibody-based tissue analysis could evaluate FAM50A as a biomarker across multiple cancer types .

• Therapeutic target validation: As FAM50A knockout impairs tumor growth, antibodies could help validate it as a potential therapeutic target by confirming protein depletion in drug development studies .

• RNA splicing dysregulation: FAM50A antibodies could help characterize splicing regulatory networks in various disease contexts, particularly those involving STAT3 signaling pathway alterations .

• Protein complex analysis: Mass spectrometry combined with FAM50A immunoprecipitation could identify novel interaction partners across different cellular contexts, potentially revealing new functional roles beyond current understanding.

What methods can researchers use to distinguish between different functional states of FAM50A protein?

As FAM50A appears to exist in different functional states depending on cellular context, researchers may employ these advanced approaches:

• Phosphorylation-specific antibodies: Development of antibodies recognizing specific post-translational modifications of FAM50A could help distinguish its different functional states.

• Proximity ligation assays: Using FAM50A antibodies in combination with antibodies against known interacting proteins to detect specific protein complexes in situ.

• FRET/BRET approaches: Utilizing antibody-based fluorescence or bioluminescence resonance energy transfer to detect conformational changes or protein interactions in live cells.

• ChIP-seq and RIP-seq: Combining FAM50A antibodies with next-generation sequencing to map genome-wide binding sites or RNA interactions under different cellular conditions.

• Super-resolution microscopy: Using highly specific FAM50A antibodies to visualize its subnuclear distribution with nanometer precision, potentially revealing functional domains within the nucleus.

Recent research has demonstrated that FAM50A regulates distinct alternative splicing events in different cellular contexts, suggesting that its function may be modulated by cellular signaling or interaction with different protein partners . Advanced antibody-based techniques could help elucidate these context-dependent activities.